Semaglutide mimics GLP-1, a hormone that regulates appetite and blood sugar
Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
MSC-Exos have demonstrated the ability to aid in the regeneration of tissue injuries in various diseases and clinical scenarios, such as wound healing, cardiovascular diseases, and COVID-19 [187]
Physical activity, though not required for weight loss, accelerates fat loss when combined with semaglutide
Also Read: Everything to Know About GLP-1 Receptor Agonist and Its Role in Weight Management GLP-1 diet mainly focuses on eating fibre-rich foods, enough protein, and balanced carbohydrates